The main office of represented VC is situated in the Beijing. The fund was located in Asia if to be more exact in China.
Among the most popular fund investment industries, there are Health Care, Biotechnology. Among the most popular portfolio startups of the fund, we may highlight Connect Biopharmaceuticals, Laekna Therapeutics. For fund there is a match between the location of its establishment and the land of its numerous investments - China. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund.
The standard case for the fund is to invest in rounds with 1-2 partakers. Despite the Anlongmed Fund, startups are often financed by C-Bridge Capital. The meaningful sponsors for the fund in investment in the same round are XinYue Equity, OrbiMed, Cowin Capital. In the next rounds fund is usually obtained by Qiming Venture Partners, Northern Light Venture Capital, Cowin Capital.
The common things for fund are deals in the range of 10 - 50 millions dollars. Speaking about the real fund results, this VC is 13 percentage points more often commits exit comparing to other organizations. The high activity for fund was in 2016. The fund is constantly included in less than 2 investment rounds annually.
Related Funds
Funds with similar focus
Fund Name | Location |
Commercial Electronics | San Antonio, Texas, United States |
Entrust Family Office | Bangalore, India, Karnataka |
Human Ventures | New York, New York, United States |
Innonic Group | Debrecen, Hajdú-Bihar, Hungary |
Jupiter Partners | New York, New York, United States |
NSFOCUS | California, Santa Clara, United States |
Unicorn Ascension Fund | India, Maharashtra, Mumbai |
UNIQUE INNOVATION FUND | - |
Wending Chuangye Touzi | Chengguan District, China, Lhasa |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Skynor Medical | 20 Jan 2021 | Shanghai, Shanghai, China | |||
Sophonix | $15M | 23 Jun 2020 | Dongcheng District, Beijing, China | ||
01 Aug 2019 | China, Shanghai | ||||
Laekna Therapeutics | $18M | 04 Jun 2018 | Shanghai, China | ||
08 May 2018 | China, Jiangsu | ||||
Sonmol | $1M | 30 Sep 2017 | China, Minhang District | ||
Hanyu Medical | 14 Sep 2017 | China, Shanghai | |||
Qianglian Zhichuang | 01 Jan 2017 | Beijing, Beijing, China | |||
Connect Biopharmaceuticals | $5M | 01 Nov 2016 | China, Tianjin |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Skynor Medical | 20 Jan 2021 | Shanghai, Shanghai, China | |||
Sophonix | $15M | 23 Jun 2020 | Dongcheng District, Beijing, China | ||
01 Aug 2019 | China, Shanghai | ||||
Laekna Therapeutics | $18M | 04 Jun 2018 | Shanghai, China | ||
08 May 2018 | China, Jiangsu | ||||
Sonmol | $1M | 30 Sep 2017 | China, Minhang District | ||
Hanyu Medical | 14 Sep 2017 | China, Shanghai | |||
Qianglian Zhichuang | 01 Jan 2017 | Beijing, Beijing, China | |||
Connect Biopharmaceuticals | $5M | 01 Nov 2016 | China, Tianjin |